Leukemia, notably Acute Myeloid Leukemia (AML), a prominent subtype, is a major health concern worldwide, marked by high mortality rates. Despite
the recent improvements of conventional treatments such as chemotherapy, there remain significant gaps in their efficacy, tolerability and resistance,
necessitating innovative therapeutic strategies. This study addresses this need by developing murine models of AML more closely emulating the clinical
setting for improved therapeutic evaluations.
The recent advancement of the Humanized Immune System (HIS) mice model has opened new horizons for cancer immunology and immunotherapy
research. By facilitating the engraftment of human tumor and immune cells, HIS models provide a platform for studying tumor-associated immunology,
immunotherapy drugs, and tumor-immune cell interactions. Its application extends to assessing immune-checkpoint inhibitors and cell therapies, in particular
CAR-T cells.
Author:
Fill out the form below to access a high resolution image of this poster: